TSX: HSM     NASDAQ: HSDT

Call us: +1 877-564-0008

divisionBanner

Stock Quote - HSM-T

*Delayed quote courtesy of Google.

Stock Quote - HSDT

*Delayed quote courtesy of Google.

NHC logo L

A division of Helius Medical Technologies (Helius), NeuroHabilitation Corporation (NHC) is developing a breakthrough technology as a potential treatment for neurological symptoms caused by disease or trauma.

In 2013, NHC signed a Collaborative Research and Development Agreement (CRADA) with the US Department of Defense to support the clinical, commercial and regulatory development of the Portable Neuromodulation Stimulator (PoNS®) Device.

PoNS_Logo_RGB.png

The PoNS device delivers translingual neurostimulation (TLNS) to potentially alter the capacity, organization and function of brain structures.

Learn About The PoNS Device